celecoxib has been researched along with thalidomide in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (58.06) | 29.6817 |
| 2010's | 13 (41.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alexandre-Moreira, MS; Augusto, CV; Barreiro, EJ; da Silva, YK; de Albuquerque Melo, GM; de Castro Barbosa, ML; de Lima Matos Freire Dias, T; de Queiroz, AC; Júnior, WB; Lima, LM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hada, M | 1 |
| Hada, M; Mizutari, K | 2 |
| Hada, M; Kazuhiro, M | 1 |
| Collins, TS; Hurwitz, HI | 1 |
| Bell, R; Catalano, J; Ganju, V; Iulio, JD; Lillie, K; Mileshkin, L; Milner, AD; Prince, HM; Ramsay, R; Roberts, A; Seymour, JF; Simmons, PJ; Underhill, C; Westerman, D; Zeldis, JB | 1 |
| Hada, M; Horiuchi, T | 1 |
| Hong, RL; Tsai, YC; Wu, CT | 1 |
| Hada, M; Horiuchi, T; Shinji, H | 1 |
| Duan, W; Kleiber, B; Kuhn, J; Otterson, G; Panico, K; Phillips, G; Schaaf, L; Shah, M; Villalona-Calero, M; Wu, WH; Young, D | 1 |
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 1 |
| Batchelor, TT; Black, PM; Bradshaw, J; Chen-Plotkin, AS; Doherty, L; Drappatz, J; Folkman, J; Gigas, DC; Kesari, S; Kieran, M; Kracher, J; Laforme, A; Levy, B; Muzikansky, A; O'Neill, A; Ramakrishna, N; Schiff, D; Weiss, SE; Wen, PY | 1 |
| Heath, J; Kanwar, VS; Krasner, CN; Pearce, JM | 1 |
| Batchelor, TT; Black, PM; Ciampa, A; Doherty, L; Drappatz, J; Folkman, J; Gigas, DC; Henson, JW; Kesari, S; Kieran, M; Laforme, A; Ligon, KL; Longtine, JA; Muzikansky, A; Ramakrishna, N; Schiff, D; Weaver, S; Wen, PY | 1 |
| Kassam, A; Mandel, K | 1 |
| Bradeen, HA; Kalof, AN; Lisle, JW | 1 |
| Bernard, C; Grushka, JR; Laberge, JM; Mueller, C; Nguyen, VH; Puligandla, PS; Roessingh, Ade B; Ryckman, J; St Vil, D; Walton, JM | 1 |
| Kivivuori, SM; Lönnqvist, T; Riikonen, P; Saarinen-Pihkala, UM; Valanne, L | 1 |
| Chang, E; Colman, H; Conrad, C; de Groot, J; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, K; Hunter, K; Levin, V; Mahajan, A; Puduvalli, V; Woo, S; Yung, WK | 1 |
| Kivivuori, SM; Nygaard, R | 1 |
| Marschner, N; Zaiss, M | 1 |
| Allen, JC; Bendel, AE; Campigotto, F; Chi, SN; Chordas, CA; Comito, MA; Goldman, S; Hubbs, SM; Isakoff, MS; Khatib, ZA; Kieran, MW; Kondrat, L; Manley, PE; Neuberg, DS; Pan, WJ; Pietrantonio, JB; Robison, NJ; Rubin, JB; Turner, CD; Werger, AM; Zimmerman, MA | 1 |
| Garami, M; Hauser, P; Pócza, T; Schuler, D; Vancsó, I | 1 |
| Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D | 1 |
| Aldape, KD; Chang, EL; Colman, H; Conrad, CA; De Groot, JF; Fisch, MJ; Floyd, JD; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, KR; Hsu, SH; Lagrone, LW; Levin, VA; Loghin, ME; Mahajan, A; Penas-Prado, M; Puduvalli, VK; Salacz, ME; Volas-Redd, G; Woo, SY; Yung, WK | 1 |
| Al-Rashood, KA; Ezzeldin, E; Iqbal, M; Shakeel, F | 1 |
| Agarwala, S; Bakhshi, S; Batra, A; Dhawan, D; Gupta, YK; Pramanik, R; Thulkar, S; Vishnubhatla, S | 1 |
3 review(s) available for celecoxib and thalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Celecoxib; Colorectal Neoplasms; Humans; Neovascularization, Pathologic; Phthalazines; Pyrazoles; Pyridines; RNA, Catalytic; Sulfonamides; Thalidomide; Vascular Endothelial Growth Factors | 2005 |
Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Celecoxib; Child; Child, Preschool; Choristoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Diagnostic Errors; Doxorubicin; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Pyrazoles; Radiography; Sulfonamides; Teratoma; Thalidomide; Thymus Gland; Thyroid Neoplasms; Thyroidectomy | 2009 |
7 trial(s) available for celecoxib and thalidomide
| Article | Year |
|---|---|
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Celecoxib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Prospective Studies; Pyrazoles; Recurrence; Risk; Sulfonamides; Thalidomide; Time Factors; Treatment Outcome | 2005 |
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Thalidomide | 2007 |
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Dacarbazine; Disease-Free Survival; DNA Methylation; Endostatins; Female; Fibroblast Growth Factor 2; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Pyrazoles; Sulfonamides; Temozolomide; Thalidomide; Thrombospondins; Vascular Endothelial Growth Factor A | 2008 |
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Celecoxib; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Isotretinoin; Kaplan-Meier Estimate; Male; Middle Aged; Neurosurgical Procedures; Pyrazoles; Radiotherapy; Sulfonamides; Supratentorial Neoplasms; Temozolomide; Thalidomide; Young Adult | 2010 |
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Fenofibrate; Follow-Up Studies; Humans; Infant; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Survival Rate; Thalidomide; Young Adult | 2014 |
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Drug Combinations; Female; Glioblastoma; Humans; Isotretinoin; Kaplan-Meier Estimate; Male; Middle Aged; Pyrazoles; Sulfonamides; Temozolomide; Thalidomide; Young Adult | 2015 |
Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Follow-Up Studies; Humans; Male; Neoplasms; Response Elements; Retreatment; Sarcoma, Ewing; Survival Rate; Thalidomide; Time Factors | 2017 |
21 other study(ies) available for celecoxib and thalidomide
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Ear; Edema; Female; Freund's Adjuvant; Hydrazones; Male; Mice; Pain; Peritonitis; Pyrazines; Rats; Rats, Wistar; Zymosan | 2010 |
[Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Camptothecin; Carcinoma, Signet Ring Cell; Celecoxib; Cisplatin; Cyclooxygenase Inhibitors; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant; Pyrazoles; Sigmoid Neoplasms; Sulfonamides; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
[A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine].
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Infusions, Intravenous; Isoenzymes; Male; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thalidomide | 2004 |
[A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase 2; Drug Administration Schedule; Female; Humans; Irinotecan; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; RNA, Messenger; Sulfonamides; Thalidomide; Tumor Necrosis Factor-alpha | 2004 |
[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Humans; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Pyrazoles; Sulfonamides; Thalidomide; Vinblastine; Vinorelbine | 2004 |
[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Pyrazoles; Sulfonamides; Thalidomide | 2005 |
Response of refractory osteosarcoma to thalidomide and celecoxib.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Celecoxib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Hip; Humans; Immunosuppressive Agents; Male; Osteosarcoma; Pyrazoles; Sulfonamides; Thalidomide; Treatment Outcome | 2005 |
[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration Schedule; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Peritoneal Neoplasms; Prognosis; Pyrazoles; Remission Induction; Sulfonamides; Thalidomide | 2006 |
Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Celecoxib; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasms; NF-kappa B; Pyrazoles; Sulfonamides; Thalidomide; Tumor Necrosis Factor-alpha | 2007 |
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |
Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Carcinoma, Small Cell; Celecoxib; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Imatinib Mesylate; Lymph Nodes; Lymphatic Metastasis; Ovarian Neoplasms; Piperazines; Pyrazoles; Pyrimidines; Sulfonamides; Thalidomide; Vinblastine | 2008 |
Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Celecoxib; Cisplatin; Disease Progression; Doxorubicin; Drug Therapy, Combination; Female; Hemangioendothelioma, Epithelioid; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Neovascularization, Pathologic; Pyrazoles; Radiography; Recombinant Proteins; Sulfonamides; Thalidomide; Vinblastine | 2008 |
Kaposiform hemangioendothelioma in multiple spinal levels without skin changes.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Tumor; Celecoxib; Child; Drug Therapy, Combination; Female; Hemangioendothelioma; Humans; Lumbar Vertebrae; Pain; Platelet Endothelial Cell Adhesion Molecule-1; Pyrazoles; Radiography; Sarcoma, Kaposi; Spinal Neoplasms; Sulfonamides; Syndrome; Thalidomide; Thoracic Vertebrae; Treatment Outcome | 2009 |
Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Celecoxib; Child; Child, Preschool; Disease Progression; Etoposide; Glioma; Humans; Pilot Projects; Pyrazoles; Quality of Life; Radiation-Sensitizing Agents; Sulfonamides; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome | 2011 |
Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy.
Topics: Administration, Metronomic; Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cerebellar Neoplasms; Cytarabine; Etoposide; Humans; Injections, Spinal; Liposomes; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neutropenia; Pyrazoles; Sulfonamides; Thalidomide; Treatment Outcome | 2012 |
Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Castration; Celecoxib; Dexamethasone; Humans; Lenalidomide; Longitudinal Studies; Lymphatic Metastasis; Male; Middle Aged; Prostatic Neoplasms; Pyrazoles; Sulfonamides; Thalidomide; Treatment Failure; Treatment Outcome | 2012 |
[Antiangiogenic treatment of pediatric CNS tumors in Hungary with the Kieran schedule].
Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow; Brain Neoplasms; Brain Stem Neoplasms; Carcinoma; Celecoxib; Cerebellar Neoplasms; Child; Child, Preschool; Choroid Plexus Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Ependymoma; Etoposide; Female; Humans; Hungary; Ischemic Attack, Transient; Male; Medulloblastoma; Neuroectodermal Tumors, Primitive; Optic Nerve Glioma; Pyrazoles; Quality of Life; Retrospective Studies; Sulfonamides; Thalidomide; Treatment Outcome | 2013 |
Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Case-Control Studies; Celecoxib; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Child, Preschool; Etoposide; Female; Follow-Up Studies; Glioma; Humans; Infant; Male; Neoplasm Grading; Prognosis; Pyrazoles; Quality of Life; Remission Induction; Sulfonamides; Survival Rate; Thalidomide; Topotecan | 2014 |
A validated UPLC-MS/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma.
Topics: Animals; Celecoxib; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; High-Throughput Screening Assays; Limit of Detection; Male; Pyrazoles; Quality Control; Rats, Wistar; Reference Standards; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry; Thalidomide | 2015 |